RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase

  RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech

Biotech Showcase 2014

Business Wire

MIRAMAR BEACH, Fla. -- January 15, 2014

Rainbow Coral Corp. (OTCBB: RBCC) joint venture partner Therakine, Ltd.,
presented its new novel drug-delivery technology at one of the world’s largest
and most important gatherings of life sciences investors this week at the
Biotech Showcase in San Francisco.

RBCC is partnering with Therakine to market and develop a revolutionary new
injectable, sustained-release technology poised to vastly improve patients’
use of a crucial drug in the fight against drug and alcohol dependence. The
joint venture plans to soon offer the only intramuscular, programmable release
of the powerful opioid receptor antagonist Naltrexone available anywhere in
the $142.5 billion drug delivery industry.

This week’s Showcase presentation could go a long way toward making the
product’s successful launch a reality.

“We’re extremely thrilled with the response we’ve received from attendees,”
said RBCC CEO Kimberly Palmer. “We’re already discussing the development of
new drug delivery programs using this same innovative protocol produced by
Therakine. I expect to begin talks soon with more potential partners that are
well-positioned to capitalize on this technological breakthrough.

“The future of this protocol is extraordinarily promising, and it has a lot of
people excited,” she continued.

Phase II of development on the drug-delivery tech is currently underway,
focusing on micronization of the technology as well as extension of its
sustained release time.

RBCC's biotech division, Rainbow BioSciences, is working with partners such as
Therakine to capitalize on the incredible growth of the global drug delivery
market by delivering new medical and research technology innovations in order
to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY),
Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Valeant
Pharmaceuticals International (NYSE: VRX).

For more information on RBCC’s other biotech initiatives, please

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(RBCC). The Company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and innovations. For
more information on our growth-oriented business initiatives, please

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.


Rainbow Coral Corp.
Kimberly Palmer, 850-269-7230
President and CEO
Press spacebar to pause and continue. Press esc to stop.